SLN
Silence Therapeutics plc (NASDAQ)
Healthcare — Biotechnology
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Price History
Fundamentals
| Market Cap | $508.95M |
| P/E Ratio (TTM) | - |
| Forward P/E | -27.63 |
| EPS (TTM) | $-1.62 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 197.20% |
| ROE | -92.56% |
| Debt/Equity | 0.28 |
| Recommendation | Buy 1.7 |
| Analyst Target | $29.17 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 83.3 |
| Beta | 1.48 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $11.06 |
| 52-Week Low | $4.19 |
| 50-Day Avg | $7.28 |
| 200-Day Avg | $6.27 |
| Avg Volume | 387.9K |
| Volume | 841.9K |
Performance Analysis
BULLISHSLN shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:31 UTC
Back to Screener Export Report